ASTAL LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.15 INR | +4.99% |
|
+15.73% | +47.61% |
| 25/05 | Astal Laboratories Limited Appoints BIRENDRAKUMAR SAHOO as Additional Non-Executive Independent Director | CI |
| 24/05 | Astal Laboratories Limited Announces Change in Corporate Office Address | CI |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 44.75 | 36.52 | 36.52 | 34.77 | 64.34 | 118.1 |
| Enterprise Value (EV) 1 | 44.67 | 36.44 | 36.38 | 34.46 | 64.16 | 117.2 |
| P/E ratio | -563 x | -43.8 x | -130 x | 577 x | -376 x | 722 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 15 x | 12.2 x | 18.1 x | 17.2 x | 30.5 x | 3.27 x |
| EV / Revenue | 14.9 x | 12.2 x | 18 x | 17.1 x | 30.4 x | 3.25 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 0.85 x | 0.7 x | 0.71 x | 0.67 x | 1.25 x | 2.27 x |
| Nbr of stocks (in thousands) | 3,974 | 3,974 | 3,974 | 3,974 | 3,974 | 3,990 |
| Reference price 2 | 11.26 | 9.190 | 9.190 | 8.750 | 16.19 | 29.60 |
| Announcement Date | 01/10/18 | 14/09/19 | 10/09/20 | 01/09/21 | 08/09/22 | 25/08/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2.991 | 2.988 | 2.019 | 2.019 | 2.108 | 36.07 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.0468 | -0.7539 | -0.2811 | 0.0811 | -0.1706 | 0.32 |
| Net income 1 | -0.066 | -0.8212 | -0.2815 | 0.0602 | -0.1711 | 0.164 |
| Net margin | -2.21% | -27.48% | -13.94% | 2.98% | -8.12% | 0.45% |
| EPS 2 | -0.0200 | -0.2100 | -0.0708 | 0.0152 | -0.0431 | 0.0410 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 01/10/18 | 14/09/19 | 10/09/20 | 01/09/21 | 08/09/22 | 25/08/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.08 | 0.08 | 0.14 | 0.31 | 0.18 | 0.84 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -0.12% | -1.57% | -0.54% | 0.12% | -0.33% | 0.32% |
| ROA (Net income/ Total Assets) | -0.12% | -1.53% | -0.53% | 0.11% | -0.32% | 0.22% |
| Assets 1 | 54.11 | 53.7 | 53.02 | 52.94 | 52.69 | 75.72 |
| Book Value Per Share 2 | 13.30 | 13.10 | 13.00 | 13.00 | 13.00 | 13.00 |
| Cash Flow per Share 2 | 0.0200 | 0.0200 | 0.0400 | 0.0800 | 0.0500 | 0.2100 |
| Capex 1 | 0.12 | - | - | - | - | - |
| Capex / Sales | 4.03% | - | - | - | - | - |
| Announcement Date | 01/10/18 | 14/09/19 | 10/09/20 | 01/09/21 | 08/09/22 | 25/08/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- MACINTR Stock
- Financials Astal Laboratories Limited
